| |
The BD FACSymphony A5 SE Cell Analyzer adds high-sensitivity detectors to detect the full spectrum of emitted light. Unmix spectral data live, all while retaining the flexibility of familiar compensation-based workflows. Learn more. 
|
|
Today's Big NewsNov 9, 2022 |
| By Annalee Armstrong A new, slimmed-down Biohaven issued its debut earnings release post-Pfizer split, touting a $301.9 million fundraising, new executive staffers and pipeline stocked with therapies to test in epilepsy and neuropsychiatric conditions. |
|
|
|
By James Waldron While the biotech bear market has forced many companies to trim back their pipelines, it’s less common to see a late-stage asset thrown on the scrapheap. But Kronos Bio has made that call for its acute myeloid leukemia drug entospletinib. |
By Nick Paul Taylor Biotech earnings season has delivered a deck of dead and deprioritized assets, with Xilio Therapeutics, Protagonist Therapeutics, Arbutus Biopharma and Aptinyx all deciding they have better uses for their cash. |
By Max Bayer Some 48 hours after Amgen touted updated phase 2 data for its Arrowhead Pharmaceuticals-partnered heart drug, Royalty Pharma is swooping in to pick up royalty rights from the small biopharma to the tune of $250 million in upfront cash. |
By Nick Paul Taylor AstraZeneca has taken a step toward winning approval of its asthma rescue medication PT027 in adults after a FDA advisory committee voted overwhelmingly that its benefits outweigh the risks. But the panel delivered a split decision on adolescent use and voted against approval in children. |
By Angus Liu After weeks of an inspection-related delay, Regeneron has finally won a much-anticipated FDA approval for Libtayo in newly diagnosed non-small cell lung cancer, opening another front to challenge Merck & Co.’s formidable Keytruda. |
By Joseph Keenan OneStudyTeam and Antidote Technologies are collaborating to help streamline clinical trial recruitment efforts for sites and sponsors. |
By Sharon Klahr Coey Basketball Hall-of-Famer Alonzo Mourning wants people to know that you can be at the top of your game yet unknowingly be suffering from kidney disease. Mourning has joined with Vertex Pharmaceuticals to raise awareness of APOL1-mediated kidney disease and the need for genetic testing and early diagnosis. |
By Andrea Park About a year after Acutus Medical’s shares first dipped below the $10 mark, the stock is now valued at a fraction of that price, putting it at risk of being booted from the Nasdaq. |
By Sharon Klahr Coey Most women past a certain age (cough) can talk about the “joys” of menopause such as hot flashes and night sweats easily, but how many can actually use the correct medical terminology—vasomotor symptoms— ascribed to those symptoms? |
By Anastassia Gliadkovskaya Reducing waste in the system has become a key priority for many healthcare organizations. Working with vendors, health systems and payers are leveraging artificial intelligence, machine learning, data analytics and other technologies to improve billing and payment processes. |
Fierce podcasts Don't miss an episode |
| This week on “The Top Line,” we dig into Philips’ revelation that it is laying off 4,000 workers and planning for even more restructuring. |
|
|---|
|
|
|
Tuesday, November 15, 2022 | 1pm ET / 10am PT In this webinar, learn how Medable is focused on improving access to clinical trials for patients, supporting the innovation of clinical trial delivery and offering greater choices for participation and engagement to patients. Register now. 
|
|
Webinar Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Presented by: Twist Bioscience |
Research Learn more about adaptive ascending dose escalation designs and considerations for determining the optimal approach to meet your drug development objectives Sponsored by: Allucent |
Whitepaper Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
Research Learn more about adaptive ascending dose escalation designs and considerations for determining the optimal approach to meet your drug development objectives Sponsored by: Allucent |
Whitepaper This paper outlines how gene therapy supply chains are different from traditional biopharma products, as well as the factors that are essential to success. Sponsored by: Blue Matter |
Video Revolutionize your monoclonal antibody (mAb) manufacturing process with the Gibco™️ Efficient-Pro™️ Medium and Feed System. Watch our how-to video. Sponsored by: Thermo Fisher Scientific |
Whitepaper What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
Research Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored By: Catalent |
Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored By: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| |
|
